Fibrogen Stock Beta
| FGEN Stock | USD 0.42 0.03 7.69% |
FibroGen fundamentals help investors to digest information that contributes to FibroGen's financial success or failures. It also enables traders to predict the movement of FibroGen Stock. The fundamental analysis module provides a way to measure FibroGen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to FibroGen stock.
FibroGen | Beta |
FibroGen Company Beta Analysis
FibroGen's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current FibroGen Beta | 0.73 |
Most of FibroGen's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, FibroGen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
FibroGen Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for FibroGen is extremely important. It helps to project a fair market value of FibroGen Stock properly, considering its historical fundamentals such as Beta. Since FibroGen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of FibroGen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of FibroGen's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, FibroGen has a Beta of 0.726. This is 15.58% lower than that of the Biotechnology sector and 47.77% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
FibroGen Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FibroGen's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FibroGen could also be used in its relative valuation, which is a method of valuing FibroGen by comparing valuation metrics of similar companies.FibroGen is currently under evaluation in beta category among its peers.
FibroGen Institutional Holders
Institutional Holdings refers to the ownership stake in FibroGen that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of FibroGen's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing FibroGen's value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.1 M | Assenagon Asset Management Sa | 2024-09-30 | 767.7 K | Renaissance Technologies Corp | 2024-09-30 | 753.1 K | Two Sigma Investments Llc | 2024-09-30 | 505.5 K | Susquehanna International Group, Llp | 2024-06-30 | 483.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 473 K | Jane Street Group Llc | 2024-06-30 | 450 K | State Street Corp | 2024-06-30 | 389.9 K | Fmr Inc | 2024-09-30 | 383.3 K | Primecap Management Company | 2024-09-30 | 9.9 M | Armistice Capital, Llc | 2024-09-30 | 6.8 M |
As returns on the market increase, FibroGen's returns are expected to increase less than the market. However, during the bear market, the loss of holding FibroGen is expected to be smaller as well.
FibroGen Fundamentals
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.97) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | (12.47 M) | ||||
| Shares Outstanding | 100.77 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 55.00 % | ||||
| Number Of Shares Shorted | 3.9 M | ||||
| Price To Earning | 97.67 X | ||||
| Price To Book | 53.83 X | ||||
| Price To Sales | 0.23 X | ||||
| Revenue | 147.75 M | ||||
| Gross Profit | (159.21 M) | ||||
| EBITDA | (261.4 M) | ||||
| Net Income | (284.23 M) | ||||
| Cash And Equivalents | 438.13 M | ||||
| Cash Per Share | 4.67 X | ||||
| Total Debt | 170.46 M | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 2.17 X | ||||
| Book Value Per Share | (2.07) X | ||||
| Cash Flow From Operations | (315.02 M) | ||||
| Short Ratio | 3.27 X | ||||
| Earnings Per Share | (1.23) X | ||||
| Target Price | 0.6 | ||||
| Number Of Employees | 486 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 39.2 M | ||||
| Total Asset | 423.53 M | ||||
| Retained Earnings | (1.84 B) | ||||
| Working Capital | 113.89 M | ||||
| Current Asset | 200.56 M | ||||
| Current Liabilities | 67.18 M | ||||
| Net Asset | 423.53 M |
About FibroGen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with FibroGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.Moving against FibroGen Stock
| 0.6 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.54 | GANX | Gain Therapeutics | PairCorr |
| 0.5 | BHC | Bausch Health Companies | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
| 0.42 | EBS | Emergent Biosolutions | PairCorr |
The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.
The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out FibroGen Piotroski F Score and FibroGen Altman Z Score analysis. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (1.23) | Revenue Per Share 1.758 | Quarterly Revenue Growth 0.143 | Return On Assets (0.27) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.